Cinven has today completed the acquisition of Bioclinica, a global provider of clinical trial services and technology to contract research organisations (CROs) and pharmaceutical companies, for an undisclosed consideration.

Cinven’s healthcare team identified Bioclinica as a compelling investment opportunity given the team’s strong track record in the clinical trials sector and direct experience through its investment in Medpace, a leading CRO business. Bioclinica operates in a number of high growth areas to improve the efficiency and productivity of clinical trials. Bioclinica benefits from structural factors including as growing clinical trial activity, increased outsourcing and the adoption of clinical software services.

Bioclinica represents the first investment from Cinven’s sixth fund.

For the latest Company news and information, follow Bioclinica on the blog at https://www.bioclinica.com/blog and on Twitter at http://twitter.com/bioclinica.

About Bioclinica

Bioclinica is an integrated clinical life science solutions provider, delivering powerful insight into clinical trial development, assuring greater client success in bringing medical therapies to market, for people around the world. Through deep medical, scientific and technology expertise, the company provides medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments; clinical trial management software; and drug safety solutions. Bioclinica’s global team of life science experts serve more than 500 pharmaceutical, biotechnology and device organizations – including the top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.

###

Media Contact
Nicole Klatsky
+1 (609) 865-5212
Email: Nicole.Klatsky@bioclinica.com

Learn more about Bioclinica at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.